CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success

Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in personalized medicine. In this strategy, a patient's own T lymphocytes are genetically reprogrammed to encode a synthetic receptor that binds a tumor antigen, allowing T cells to recognize and kill antigen-expressing...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Kristen B., Young, Regina M., Boesteanu, Alina C., Davis, Megan M., Melenhorst, J. Joseph, Lacey, Simon F., DeGaramo, David A., Levine, Bruce L., Fraietta, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287001/
https://www.ncbi.nlm.nih.gov/pubmed/30559740
http://dx.doi.org/10.3389/fimmu.2018.02740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287001/
https://www.ncbi.nlm.nih.gov/pubmed/30559740
http://dx.doi.org/10.3389/fimmu.2018.02740

Ejemplares similares